Fifth Third Bancorp Common Stock vs Novavax Inc — how do they compare? Fifth Third Bancorp Common Stock trades at $50.38 (market cap $45.98B), while Novavax Inc trades at $12.61 (market cap $1.82B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 25.3× Novavax Inc's market cap, and Fifth Third Bancorp Common Stock pays a 3.31% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| FITB | NVAX | |
|---|---|---|
Market Cap | $45.98B | $1.82B |
Volume | 10,522,320 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $59.37 | $12.56 |
52-Week Low | $40.36 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $63.85B | $1.39B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →